Antipodes Exited Sanofi (SNY) After Repeated Pipeline Setbacks

3 weeks ago 14

Soumya Eswaran

Thu, August 6, 2026 astatine 6:58 AM CDT 3 min read

Antipodes Partners published its "Antipodes Global Strategy" second-quarter 2026 capitalist letter, highlighting the cardinal show stocks, portfolio changes, and the marketplace outlook. A transcript of the missive tin be downloaded here. The 2nd 4th of 2026 delivered 1 of the strongest equity marketplace recoveries successful caller history, arsenic planetary equities gained 14.9% successful US dollar terms. Renewed enthusiasm for artificial intelligence, beardown firm earnings, and easing tensions with Iran supported the rebound, portion maturation stocks outperformed worth and emerging markets led gains, peculiarly Korea and Taiwan. The Antipodes Global Value Strategy underperformed its benchmark during the 4th and implicit the 12 months to June 30, 2026, arsenic returns became concentrated successful a constrictive radical of semiconductor and hardware stocks. Consumer staples and user discretionary holdings supported performance, portion accusation technology, software, and net vulnerability detracted. The steadfast remains cautious connected costly representation companies due to the fact that pricing and proviso stay cyclical contempt AI demand. The Strategy continues to favour valued infrastructure, specialty semiconductors, resilient software, and prime businesses. For insights into its cardinal selections for 2026, delight reappraisal the Strategy's apical 5 holdings.

In its second-quarter 2026 capitalist letter, Antipodes Global Value Strategy highlighted Sanofi (NASDAQ:SNY). Sanofi (NASDAQ:SNY) is simply a French pharmaceutical and healthcare institution that engages successful the research, development, manufacture, and selling of therapeutic solutions. On August 5, 2026, Sanofi (NASDAQ:SNY) closed astatine $42.78 per share. The one-month instrumentality of Sanofi (NASDAQ:SNY) was -2.55%, and its shares mislaid 9.80% implicit the past 52 weeks. Sanofi (NASDAQ:SNY) has a marketplace capitalization of $102.51 billion.

Antipodes Global Value Strategy stated the pursuing regarding Sanofi (NASDAQ:SNY) in its Q2 2026 capitalist letter:

"Sanofi (NASDAQ:SNY) (Exit): We exited Sanofi pursuing a bid of pipeline disappointments, which impacted our assurance successful Sanofi's quality to negociate the Dupixent nonaccomplishment of exclusivity. Any R&D turnaround is apt to beryllium a multi-year endeavour relying connected concern development, for which the company's caller way grounds has been poor."

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?

Sanofi (NASDAQ:SNY) is not on our database of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge money portfolios held Sanofi (NASDAQ:SNY) at the extremity of the first quarter which was 32 in the erstwhile quarter. While we admit the imaginable of Sanofi (NASDAQ:SNY) as an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article